Summary Slide.png (111.98 kB)

Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis

figure

posted on 2020-08-28, 12:42 authored by Ataru Igarashi, Barnaby Hunt, Lars Wilkinson, Jakob Langer, Richard F. Pollock

The above Summary Slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

References

https://link.springer.com/article/10.1007/s12325-020-01476-x

Usage metrics

Read the peer-reviewed publication

Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis

Advances in Therapy

Keywords

Cost-benefit Costs and Cost Analysiss Diabetes mellitus Glucagon-like peptides Japan Semaglutide Type 2

Licence

CC BY-NC 4.0

Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis

History

References

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports